Ally had raised $10m in seed funding from investors including UCB but disappointing animal studies led the company to be wound down.
Ally Therapeutics, a US-based gene therapy developer backed by biopharmaceutical company UCB, has halted operations, Endpoints News reported yesterday.
The spinout shut down “earlier this year” following disappointing results in animal trials.
Founded in 2018, Ally Therapeutics was looking to prevent an immune response to gene therapies. It was based on research from Ying Kai Chan, a postdoctoral researcher in Harvard University’s lab of George Church, himself a prolific entrepreneur who has co-founded dozens of spinouts.
Arch Venture Partners led…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
